Chief Medical Officer · Fulcrum Therapeutics, Inc. (FULC)

Christopher Morabito

FY2021 is the first fiscal year CompBrief holds for Christopher Morabito as a named executive officer of Fulcrum Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,664,108

Salary $274,479Stock awards $0

4th of 4 named executive officers at Fulcrum Therapeutics by FY2021 total.

4 named officers on file for Fulcrum Therapeutics, FY2021

Christopher Morabito’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Fulcrum Therapeutics’s whole pay program stands against its peers

  • Fulcrum Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FULC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Christopher Morabito’s full pay file as a PDF — free

More than this page: up to 10 years of Christopher’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Christopher Morabito compensation by year

Fulcrum Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Fulcrum Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$274,479
Stock awards$0
Option awards$1,185,629
Non-equity incentive$204,000
Pension and deferred compensation$0
All other$0
Total$1,664,108

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Fulcrum Therapeutics, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127507, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Fulcrum Therapeutics, Inc. filed document, accession 0001193125-22-127507. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option163,000—$10.01

Per the Outstanding Equity Awards at Fiscal Year-End table in Fulcrum Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Fulcrum Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Bryan StuartPresident and Chief Executive Officer$5,055,104
Judith DunnPresident, Research and Development$2,430,128
Robert GouldFormer President and Chief Executive Officer$2,341,739
Christopher Morabito · this pageChief Medical Officer$1,664,108

The full Fulcrum Therapeutics compensation record

free company brief

This page is one person within Fulcrum Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Fulcrum Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Morabito's compensation dossier · One-time report. No refunds.